To date, the clinico-association of glypican-1 with disease activity in SLE or LN patients has not been documented, and further studies are warranted to determine the association of glycocalyx-associated glypican-1 and vascular stiffness in LN patients. This evidence concerns the gene GPC1 and systemic lupus erythematosus.